Logotype for Harvard Bioscience Inc

Harvard Bioscience (HBIO) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Harvard Bioscience Inc

Q3 2026 earnings summary

10 Nov, 2026

Executive summary

  • Q3 revenue rose 7.8% YoY to $22.2M, marking a second consecutive quarter of growth; CRO, China and distribution demand supported sales.

  • Adjusted EBITDA was $1.8M; lower-margin product and channel mix pressured margins and led to a cut in FY26 adjusted EBITDA growth guidance.

  • Nine-month revenue increased 4.6% to $65.7M; net loss was $9.0M, with prior-year results affected by a $48.0M goodwill impairment.

Financial highlights

  • Q3 GAAP gross margin was 55.4% vs. 58.4%; adjusted gross margin was 57.1% vs. 59.2%.

  • Operating loss was $1.2M vs. $0.2M operating income; adjusted operating income was $1.2M vs. $1.5M.

  • Adjusted EBITDA was $1.8M vs. $2.0M; adjusted EBITDA margin was 7.9% vs. 9.6%.

  • Net loss was $2.6M vs. $1.2M; GAAP diluted loss per share was $0.58 vs. $0.28, and adjusted diluted loss per share was $0.06 vs. $0.04.

  • Nine-month operating loss was $3.3M vs. $50.3M; nine-month net loss was $9.0M vs. $53.9M.

Outlook and guidance

  • FY26 revenue growth guidance remains 3%–5% and adjusted gross margin guidance 57%–59%; adjusted EBITDA growth guidance was cut to -1%–4% from 6%–10%.

  • Q4 revenue guidance is $23.7M–$25.5M, adjusted gross margin 59%–61%, and adjusted EBITDA $3.8M–$4.2M.

  • Q4 outlook anticipates YoY revenue growth across CMT and NPI platforms, sequential adjusted gross-margin expansion and improving YoY adjusted EBITDA profitability.

  • Management expects gross margin in the 60% range in 2027; ~75% of Project Viking benefits relate to gross margin.

  • Project Viking is expected to save $3M in 2027 and $4M annually from 2028.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Harvard Bioscience